Ebola virus vaccines: an overview of current approaches

被引:103
作者
Marzi, Andrea [1 ]
Feldmann, Heinz [1 ]
机构
[1] NIAID, Virol Lab, Div Intramural Res, NIH,Rocky Mt Labs, Hamilton, MT 59840 USA
关键词
animal model; vaccine; prophylaxis; Ebola virus; filovirus; PROTECTS NONHUMAN-PRIMATES; EQUINE ENCEPHALITIS-VIRUS; ADENOVIRUS-BASED VACCINE; RESPIRATORY-TRACT IMMUNIZATION; MARBURG VIRUS; HEMORRHAGIC-FEVER; GUINEA-PIGS; IMMUNE-RESPONSES; VECTORED VACCINE; DNA VACCINE;
D O I
10.1586/14760584.2014.885841
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Ebola hemorrhagic fever is one of the most fatal viral diseases worldwide affecting humans and nonhuman primates. Although infections only occur frequently in Central Africa, the virus has the potential to spread globally and is classified as a category A pathogen that could be misused as a bioterrorism agent. As of today there is no vaccine or treatment licensed to counteract Ebola virus infections. DNA, subunit and several viral vector approaches, replicating and non-replicating, have been tested as potential vaccine platforms and their protective efficacy has been evaluated in nonhuman primate models for Ebola virus infections, which closely resemble disease progression in humans. Though these vaccine platforms seem to confer protection through different mechanisms, several of them are efficacious against lethal disease in nonhuman primates attesting that vaccination against Ebola virus infections is feasible.
引用
收藏
页码:521 / 531
页数:11
相关论文
共 76 条
[71]   Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection [J].
Warfield, KL ;
Olinger, G ;
Deal, EM ;
Swenson, DL ;
Bailey, M ;
Negley, DL ;
Hart, MK ;
Bavari, S .
JOURNAL OF IMMUNOLOGY, 2005, 175 (02) :1184-1191
[72]   Ebola virus-like particles protect from lethal Ebola virus infection [J].
Warfield, KL ;
Bosio, CM ;
Welcher, BC ;
Deal, EM ;
Mohamadzadeh, M ;
Schmaljohn, A ;
Aman, MJ ;
Bavari, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (26) :15889-15894
[73]   Vaccine potential of Ebola virus VP24, VP30, VP36, and VP40 proteins [J].
Wilson, JA ;
Bray, M ;
Bakken, R ;
Hart, MK .
VIROLOGY, 2001, 286 (02) :384-390
[74]   Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein [J].
Wilson, JA ;
Hart, MK .
JOURNAL OF VIROLOGY, 2001, 75 (06) :2660-2664
[75]  
Wong G, 2012, SCI TRANSL MED, V4
[76]   Ad35 and Ad26 Vaccine Vectors Induce Potent and Cross-Reactive Antibody and T-Cell Responses to Multiple Filovirus Species [J].
Zahn, Roland ;
Gillisen, Gert ;
Roos, Anna ;
Koning, Marina ;
van der Helm, Esmeralda ;
Spek, Dirk ;
Weijtens, Mo ;
Pau, Maria Grazia ;
Radosevic, Katarina ;
Weverling, Gerrit Jan ;
Custers, Jerome ;
Vellinga, Jort ;
Schuitemaker, Hanneke ;
Goudsmit, Jaap ;
Rodriguez, Ariane .
PLOS ONE, 2012, 7 (12)